Company intelligence / Profile preview

YiChang HEC ChangJiang Pharmaceutical

Yichang, Hubei, China

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Strong sales leadership in anti-influenza (oseltamivir phosphate/Kewei); advancing HCV DAAs and full biosimilar insulin portfolio with up to 100% SVR12 in Phase 2 for key HCV candidate (yimitasvir phosphate); recombinant insulins reported comparable safety/effectiveness to original brand standards.

Therapeutic areas: CardiovascularInfectious DiseasesEndocrinology
Modalities: Small moleculeBiologicRecombinant proteinBiosimilar
Industry: Pharma

Drug pipeline

4 assets

yimitasvir

3 more assets in the full pipeline.

Request access →

Partnerships

Sunshine Lake Pharma (strategic R&D/commercial partnership, parent/shareholder)Various research collaborations

Beyond the preview

Go deeper on YiChang HEC ChangJiang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YiChang HEC ChangJiang Pharmaceutical.

Explore the full profile